Ethicon Launches New Power Stapler Enabling Extra Control and Precision for Complex Surgeries

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

The ECHELON FLEX™ GST System now features a 45mm endocutter intended for use in very thick tissue[5], making it suitable across a range of specialties

Ethicon today announced the launch of its ECHELON FLEX™ GST System (45mm) across Europe. With this addition, the ECHELON FLEX™ GST System now offers both 45mm and 60mm endocutters with reloads, which is of mounting importance as more complex surgeries are being performed through minimally invasive approaches.

The increasing prevalence of lung and bowel cancer, in conjunction with rising rates of obesity could mean that more patients will need surgery. Bowel and lung cancer are the first and second most common forms of cancer in Europe, affecting 471,00[1] and 449 000[1] people each year respectively – while obesity rates have also risen dramatically, nearly doubling between 1980 and 2008, with roughly 23% of women and 20% of men now classified as clinically obese[2]. Many of these patients have specific needs during surgery due to diseased or therapeutically compromised tissue, and consequently, surgeons need equipment that will allow extra control and precision.

Silvia De Dominicis, Ethicon Franchise Vice President for EMEA said, “The addition of 45mm length to the ECHELON FLEX™ GST portfolio is a demonstration of Ethicon’s commitment to addressing increasingly complex variables in oncology and metabolic surgical cases, while the wider range of reload selection means surgeons may have the ability to select the most optimal reload and length.” De Dominicis concluded,  “With the prevalence of disease states such as cancer and obesity steadily rising, we will continue to innovate to help support health systems in meeting the Triple Aim goals of reducing costs, enhancing patient outcomes and increasing patient satisfaction.”

Exceptional staple line integrity now across a range of tissue thicknesses with each reload[3], the ECHELON FLEX™ GST System (60mm) controls tissue movement with pre-compression and Gripping Surface Technology, and has shown to capture both layers of the mucosa during firing better than the other leading endocutter on the market, designed to optimize tissue for healing[4].


1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012

2. World Health Organization. Obesity Factsheet

3. Porcine tissue thickness measured at 8g/mm2 prior to firing.  Tissue comfortably compressed to closed staple height per IFU. PRC066855 Design Verification Test. August 2014. PRC076031 Tissue Performance Design Verification Test of 45mm Gripping Surface Technology (GST) Reloads with Echelon Flex 45mm Powered Plus Staplers. September 2016. Ethicon Data on File (020293-161103)

4. GST System Blue and Green Reloads compared to Endo GIA with Tri Staple™ Technology Purple Reloads evaluated via gross observations of firings in 1.5mm to 3.0mm thick animate porcine ileum.  Average apposition ratings 2.81 (GST60B) and 2.56 (GST60G) vs 3.23 (EGIA60AMT), p=0.001. PSB004500 – Compare compression damage and mucosal injury created during the firing of endoscopic stapling devices. August 2016. Ethicon Data on File (057886-160810)

5. Very thick tissue = max 4.2mm open staple height / max 2.3mm closed staple height (with a Black GST Reload), according to IFU GST45 P000143P01. Please refer always to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.